期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

基因突变与甲状腺癌诊断及预后 被引量：2

原文传递
导出
摘要 甲状腺结节是一种常见疾病,虽然细针穿刺细胞学检查是目前甲状腺结节性质判定的重要辅助检查,然而10％～40％甲状腺结节通过穿刺细胞学无法判断性质.另外,甲状腺癌发病率的增加几乎全部归因于甲状腺乳头状癌发病率的增加,目前对具备不良预后特征的高危甲状腺乳头状癌患者采取更积极的治疗方式越来越被认同.本文就甲状腺癌中常见的基因突变与甲状腺癌诊断、预后之间相关性最新的研究进展做一综述.
作者 万汉锋 张彬
机构地区 北京协和医学院中国医学科学院肿瘤医院头颈外科
出处 《国际耳鼻咽喉头颈外科杂志》 2013年第4期234-236,共3页 International Journal of Otolaryngology-Head and Neck Surgery
关键词 基因(Gene) 突变(Mutation) 甲状腺肿瘤(Thyroid Neoplasms)
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1连小兰.美国《甲状腺结节和分化型甲状腺癌诊治指南(2006)》解读[J].中国实用外科杂志,2007,27(12):933-936. 被引量：61
  • 2Hegedus L.Clinical practice.The thyroid nodule.N Engl J Med,2004,351 (17):1764-1771.
  • 3Davies L,Welch HG.Increasing incidence of thyroid cancer in the United States.JAMA,2006,295 (18):2164-2167.
  • 4Cooper DS,Doherty GM,Haugen BR,et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid,2009,19 (11):1167-1214.
  • 5Cooper DS,Doherty GM,Haugen BR,et al.Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid,2006,16 (2):109-142.
  • 6Garnett M J,Marais R.Guilty as charged:B-RAF is a human oncogene.Cancer Cell,2004,6 (4):313-319.
  • 7Lee JH,Lee ES,Kim YS.Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid:a meta-analysis.Cancer,2007,110 (1):38-46.
  • 8Yip L,Nikiforova MN,Carty SE,et al.Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.Surgery,2009,146 (6):1215-1223.
  • 9Nikiforova MN,Kimura ET,Gandhi M,et al.BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.J Clin Endocrinol Metab,2003,88(11):5399-5404.
  • 10Mazzaferri EL,Jhiang SM.Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.Am J Med,1994,97 (5):418-428.

二级参考文献8

  • 1McNeil C. Annual cancer statistics report raises key questions [J]. J Natl Cancer Inst,2006,98(22):1598-1599.
  • 2Burgess JR ,Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology[J]. Thyroid,2006,16 (1):47-53.
  • 3Regional Thyroid Cancer Group. Northern Cancer Network guide-lines for management of thyroid cancer[J]. Clin Oncol (R Coll Radiol) ,2000,12(6) :373-391.
  • 4AACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists and Associazione Medici Endo-crinology medical guidelines for clinical practice for the diagnosis and management of thyroid nodules [J]. Endocr Pract, 2006,12(1):63-102.
  • 5Thyroid Carcinoma Task Force guidelines for clinical practice AACE/AAES medical/surgical management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology [J]. Endoer Pract, 2001,7(3):202-220.
  • 6Watkinson JC. British Thyroid Association. The British Thyroid Association guidelines for the management of thyroid cancer in adults [J]. Nucl Med Commun ,2004,25(9):897-900.
  • 7Franklyn JA. Comparing USA and UK guidelines for the management of differentiated thyroidcarcinoma [J]. Thyroid, 2006,16(2):105-107.
  • 8Cooper DS, Doherty GM, Haugen BR, et al. The American Thyroid Association Guidelines Taskforee. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer [J]. Thyroid,2006,16(2):109-142.

共引文献60

同被引文献17

  • 1朱晓丽,周晓燕,朱雄增.甲状腺乳头状癌中BRAF^(V599E)点突变与RET/PTC融合基因的检测[J].中华病理学杂志,2005,34(5):270-274. 被引量：30
  • 2罗书画,周扬,龚日祥.BRAF基因与甲状腺癌[J].现代预防医学,2007,34(1):64-66. 被引量：4
  • 3Cooper DS,Doherty GM,Haugen BR,et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2009,19 (11):1167-1214.
  • 4Cooper DS,Doherty GM,Haugen BR,et al.Management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2006,16 (2):109-142.
  • 5Gamett MJ,Marais R.Guilty as charged:B-RAF is a human oncogene[J].Cancer Cell,2004,6(4):313-319.
  • 6Nam SY,Han BK,Ko EY,et al.BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification:a potential guide for selection of samples for molecular analysis[J].Thyroid,2010,20 (3):273-279.
  • 7Chung KW,Yang SK,Lee GK,et al.Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis,especially in BRAF600E mutation-prevalent area[J].Clin Endocrinol (Oxf),2006,65 (6):660-666.
  • 8Nikiforov YE,Steward DL,Robinson-Smith TM,et al.Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules[J].J Clin Endocrinol Metab,2009,94 (6):2092-2098.
  • 9Koh J,Choi JR,Han KH,et al.Proper indication of BRAF (V600E) mutation testing in fine-needle aspirates of thyroid nodules[J].PLoS One,2013,8(5):e64505.
  • 10Cibas ES,Ali SZ.The Bethesda system for reporting thyroid cytopathology[J].Thyroid,2009,19 (11):1159-1165.

引证文献2

二级引证文献31

国际耳鼻咽喉头颈外科杂志
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部